NTRA250117P130000
- 1.21
- 0.000.00%
Natera Newsroom
Express News | Natera Shares Are Trading Higher After the Company Announced It Will Reveal New Insights and Innovations for Tissue-free MRD at ASCO GI 2025
BTIG Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $185
Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and Natera (NTRA)
Natera to Present New Data at the 2025 ASCO GI Symposium
Looking Into Natera's Recent Short Interest
The End Of The 60/40 Portfolio
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday
Natera Analyst Ratings
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
Guggenheim Maintains Natera(NTRA.US) With Buy Rating, Announces Target Price $200
Express News | Natera Inc : Guggenheim Raises Target Price to $200 From $170
US MOVERS&SHAKERS Jan 13-Jan 17, 2025
Australia Non-Invasive Prenatal Testing (NIPT) Market Forecast, 2024-2033 With F. Hoffmann-La Roche, Virtus Health, Illumina, BGI, Natera, Monash IVF Group Leading - ResearchAndMarkets.com
Bernstein Keeps Their Buy Rating on Natera (NTRA)
Express News | Natera To Provide Roadmap And Outlook At J.P. Morgan Healthcare Conference
Natera's Strong Market Position and Growth Potential Drive Buy Rating
Natera Announces Innovation Roadmap, With Advancements in MRD and Early Cancer Detection
Express News | Natera Shares Are Trading Higher After JP Morgan Upgraded the Stock From Underweight to Neutral and Raised Its Price Target From $40 to $50
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $210
Natera Shares Are Trading Higher After the Company Reported Preliminary FY24 Financial Results.